About

Publication thumbnail: Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus

Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus

Publication thumbnail: Relationship Between the EULAR/ACR Classification Criteria and Organ Damage in Systemic Lupus Erythematosus

Relationship Between the EULAR/ACR Classification Criteria and Organ Damage in Systemic Lupus Erythematosus

Aurinia Announces European Approval of LUPKYNIS (voclosporin)

Jourde-Chiche et al, 2022

van Vollenhoven et al, 2022

Dörner et al, 2022

Literature Highlights, July 2022

Furie et al, 2021

Literature Highlights, October 2021

Iolascon et al, 2021

Isenberg et al, 2021